In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it
Peptide therapy success stories -we don't publish testimonials that overstate results, but we do see satisfied clients who appreciate our honest approach and tailored protocols
1 Dwa dni prelekcji, paneli dyskusyjnych i networkingu, ktre zmieni Twoje spojrzenie na strategi firmy
Improving protocols for PRP preparation and administration in patellar tendinopathy A major challenge in studying the efficacy of PRP in patellar tendinopathy is the lack of standardized protocols for preparing and administering PRP and the absence of protocol regarding uniformity on the correct amount and number of dosages
To determine the effect of RhoA on OA in vivo, OA progression in mice 8 weeks post-DMM was assessed using H&E, safranin-O-fast green and Masson staining
Break TJ, Witter AR, Indramohan M, Mummert ME, Dory L, Berg RE